1. Shigella ubiquitin ligase IpaH7.8 targets gasdermin D for degradation to prevent pyroptosis and enable infection.
- Author
-
Luchetti G, Roncaioli JL, Chavez RA, Schubert AF, Kofoed EM, Reja R, Cheung TK, Liang Y, Webster JD, Lehoux I, Skippington E, Reeder J, Haley B, Tan MW, Rose CM, Newton K, Kayagaki N, Vance RE, and Dixit VM
- Subjects
- Animals, Bacterial Proteins genetics, Dysentery, Bacillary genetics, Dysentery, Bacillary microbiology, Epithelial Cells metabolism, Epithelial Cells microbiology, Female, Host-Pathogen Interactions, Humans, Mice, Mice, Knockout, Phosphate-Binding Proteins genetics, Pore Forming Cytotoxic Proteins genetics, Proteolysis, Shigella flexneri genetics, Shigella flexneri physiology, Ubiquitin-Protein Ligases genetics, Bacterial Proteins metabolism, Dysentery, Bacillary metabolism, Phosphate-Binding Proteins metabolism, Pore Forming Cytotoxic Proteins metabolism, Shigella flexneri enzymology, Ubiquitin-Protein Ligases metabolism
- Abstract
The pore-forming protein gasdermin D (GSDMD) executes lytic cell death called pyroptosis to eliminate the replicative niche of intracellular pathogens. Evolution favors pathogens that circumvent this host defense mechanism. Here, we show that the Shigella ubiquitin ligase IpaH7.8 functions as an inhibitor of GSDMD. Shigella is an enteroinvasive bacterium that causes hemorrhagic gastroenteritis in primates, but not rodents. IpaH7.8 contributes to species specificity by ubiquitinating human, but not mouse, GSDMD and targeting it for proteasomal degradation. Accordingly, infection of human epithelial cells with IpaH7.8-deficient Shigella flexneri results in increased GSDMD-dependent cell death compared with wild type. Consistent with pyroptosis contributing to murine disease resistance, eliminating GSDMD from NLRC4-deficient mice, which are already sensitized to oral infection with Shigella flexneri, leads to further enhanced bacterial replication and increased disease severity. This work highlights a species-specific pathogen arms race focused on maintenance of host cell viability., Competing Interests: Declaration of interests All authors except J.R., R.A.C., and R.E.V. are employees of Genentech. R.E.V. is an investigator of the Howard Hughes Medical Institute and a consultant for Ventus Therapeutics and Tempest Therapeutics., (Copyright © 2021 Genentech. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF